PIB Bulletin Update on COVID-19

By
Saurabh
-
0
260
PIB’S BULLETIN ON COVID-19
PIB’S BULLETIN ON COVID-19

PIB News Update:

  • India’s Active Caseload Declines for the Second Consecutive day
  • WHO has not associated the term “Indian Variant” with B.1.617, now classified as Variant of Concern
  • Government to ramp up availability of Amphotericin B – to fight Mucormycosis

#Unite2FightCorona

#IndiaFightsCorona

 

 

 

PRESS INFORMATION BUREAU

MINISTRY OF INFORMATION AND BROADCASTING

GOVERNMENT OF INDIA

 

 

 

India’s Active Caseload Declines for the Second Consecutive day

 

  • New Recoveries outnumber Daily New COVID Cases for the Second Consecutive day
  • India’s Cumulative Vaccination Coverage exceeds 17.5 Crore
  • More than 30 lakh beneficiaries of age group 18-44 Vaccinated so far
  • The National Recovery Rate is 83.04%.
  • The National Mortality Rate currently stands at 1.09%.

For details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717870

 

WHO has not associated the term “Indian Variant” with B.1.617, now classified as Variant of Concern

This is to clarify that WHO has not associated the term “Indian Variant” with the B.1.617 variant of the coronavirus in its 32 page document.

For Details :https://pib.gov.in/PressReleasePage.aspx?PRID=1717876

Ministry of Power takes proactive measures to ensure 24×7 power supply to Oxygen Power Plants in the Country

In view of the pan India impact of the second wave of corona virus pandemic across the country and the manifold rise in oxygen demand for both medical facilities and for home treatment of patients , the Ministry of Power has undertaken a number of pro-active preventive and remedial measures to ensure that there is uninterrupted power supply to Oxygen Plants by the State Utilities

For Details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717861

 

Government take steps to ramp up availability of Amphotericin B – to fight Mucormycosis
A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication. The Government of India is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra imports of this drug and increase in its production domestically.

For Details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717864

 

 

 

PIB FACT CHECK

 

 

 

 

 

 

 

Previous articleResearch | Previously unrecognized tsunami hazard identified in coastal cities
Next articleTRIFED | Organising State level Webinars
Saurabh
Saurabh
Saurabh Sinha, Editor of IndianBureaucracy.com, is known for his credible, precise and insightful coverage of governance, civil services and administrative developments in India. Under his leadership, the portal has grown into a trusted national platform for accurate updates, appointments and policy movements within the bureaucratic ecosystem. Saurabh’s strong professional networking and deep understanding of government functioning enable him to present timely, reliable and well-contextualised information to readers across sectors. As a thought-driven editor, he promotes informed dialogue on governance reforms while maintaining high editorial standards. His calm, consistent and detail-oriented approach continues to strengthen the portal’s reputation. इंडियनब्यूरोक्रेसी.कॉम के संपादक सौरभ सिन्हा देश की नौकरशाही, शासन व्यवस्था और प्रशासनिक गतिविधियों की विश्वसनीय तथा संतुलित रिपोर्टिंग के लिए जाने जाते हैं। उनके नेतृत्व में यह पोर्टल नियुक्तियों, नीतिगत बदलावों और प्रशासनिक खबरों का एक भरोसेमंद राष्ट्रीय स्रोत बन चुका है। शासन तंत्र की गहरी समझ और मजबूत पेशेवर नेटवर्क के कारण सौरभ पाठकों को समयबद्ध, सटीक और संदर्भित जानकारी प्रदान करते हैं। एक विचारशील संपादक के रूप में वे सुशासन, पारदर्शिता और सुधारों पर सकारात्मक संवाद को बढ़ावा देते हैं। उनकी शांत, सूक्ष्म और पेशेवर संपादकीय शैली पोर्टल की प्रतिष्ठा को लगातार मजबूत कर रही है।
Linkedin